

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

METRONIDAZOLE TABLETS BP 200mg

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 200mg Metronidazole PhEur.

3 PHARMACEUTICAL FORM

White film-coated tablets.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Metronidazole is active against a wide range of pathogenic micro-organisms, notably species of *Bacteroids*, *Fusobacteria*, *Clostridia*, *Eubacteria*, anaerobic cocci and *Gardnerella vaginalis*.

It is also active against *Trichomonas vaginalis*, *Entamoeba histolytica*, *Gardia lamblia*, *Balantidium coli* and *Helicobacter pylori*.

Indications are:

- 1) Prevention of post-operative infections due to anaerobic bacteria, particularly species of *bacteroids* and anaerobic streptococci.
- 2) The treatment of septicaemia, bacteraemia, peritonitis, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and post-operative wound infections from which pathogenic anaerobes have been isolated.
- 3) Urogenital trichomoniasis in the female (*Trichomonas vaginalis*), and in man.
- 4) Bacterial vaginosis (also known as non-specific vaginitis, anaerobic vaginosis or *Gardnerella vaginalis*).
- 5) All forms of amoebiasis (intestinal and extra-intestinal disease and asymptomatic cyst passers).
- 6) Giardiasis.
- 7) Acute ulcerative gingivitis.
- 8) Acute dental infections (*eg* acute pericoronitis and acute apical infections)
- 9) Anaerobically-infected leg ulcers and pressure sores.
- 10) Treatment of *Helicobacter pylori* infection associated with peptic ulcer as part of triple therapy.

4.2 Posology and method of administration

Posology

Metronidazole Tablets should be taken during or after meals, swallowed with water and NOT CHEWED.

Elderly: Caution is advised in the elderly, particularly at high doses, although there is limited information available on modification of dosage.

Hepatic impairment: Caution is advised in patients with hepatic encephalopathy. One third of the daily dose given once a day should be considered (see section 4.4).

1) Anaerobic infections:

Treatment for 7 days should be satisfactory for most patients but, depending upon clinical and bacteriological assessments, the physician may decide to prolong treatment, *eg* for eradication of infection from sites which cannot be drained or are liable to endogenous recontamination by anaerobic pathogens from the gut, oropharynx or genital tract.

Prophylaxis against anaerobic infection - chiefly in the context of abdominal (especially colorectal) and gynaecological surgery.

Adults and children over 10 years: 1g stat dose 24 hours pre-operatively, followed by 400mg at 8 hourly intervals during the 24 hours preceding operation followed by post-operative iv or rectal administration until the patient is able to take tablets.

Children under 10 years: A more suitable dosage form should be used for this age group.

2) Treatment of established infections:

Adults and children over 10 years: 800mg followed by 400mg 8 hourly.

Children under 10 years: A more suitable dosage form should be used for this age group.

3) Urogenital trichomoniasis: Where reinfection is likely, sexual partners should be treated concomitantly.

Adults and children over 10 years: 200mg three times daily or 400mg twice daily for 7 days; or 800mg in the morning and 1200mg in the evening for 2 days; or 2g as a single dose for one day only.

Children under 10 years: A more suitable dosage form should be used for this age group.

4) Bacterial vaginosis

Adults and children over 10 years: 400mg twice daily for 7 days, or 2g as a single dose for one day only.

5) Amoebiasis

a) Invasive intestinal disease in susceptible subjects:

Adults and children over 10 years: 800mg three times daily for 5 days.

Children 7-10 years: 400mg three times daily for 5 days.

Children under 7 years: A more suitable dosage form should be used for this age group.

b) Intestinal disease in less susceptible subjects and chronic amoebic hepatitis (for 5-10 day duration), and amoebic liver abscess and other forms of extra-intestinal amoebiasis (for 5 day duration):

Adults and children over 10 years: 400mg three times daily.

Children 7-10 years: 200mg three times daily.

Children under 7 years: A more suitable dosage form should be used for this age group.

c) *Asymptomatic cyst passers (for 5-10 day duration):*

Adults and children over 10 years: 400-800mg three times daily.

Children 7-10 years: 200-400mg three times daily.

Children under 7 years: A more suitable dosage form should be used for this age group.

6) *Giardiasis:*

Adults and children over 10 years: 2g once daily for 3 days or 400mg three times a day for 5 days.

Children 7-10 years: 1g once daily for 3 days or 200mg once daily for 10 days.

Children under 7 years: A more suitable dosage form should be used for this age group.

7) *Acute ulcerative gingivitis (for 3 day duration):*

Adults and children over 10 years: 200mg three times daily.

Children under 10 years: A more suitable dosage form should be used for this age.

8) *Acute dental infections (for 3-7 day duration):*

Adults and children over 10 years: 200mg three times daily.

9) *Leg ulcers and pressure sores (for 7 day duration):*

Adults and children over 10 years: 400mg three times daily.

10) *Treatment of Helicobacter pylori in infected patients*

Generally Metronidazole treatment should be given in triple combination with other agents recommended for use in the treatment of Helicobacter pylori.

Depending on triple therapy used doses are either 400mg – 500mg two or three times a day for 7-14 days.

Method of Administration

For oral administration.

4.3 Contraindications

- Known hypersensitivity to metronidazole or any of the ingredients in the tablets.
- Pregnancy - metronidazole should not be used in the first trimester in patients with trichomoniasis or bacterial vaginosis (see section 4.6).
- Breast feeding should be discontinued for 12-24 hours when single high dose (e.g. 2g) therapy is used (see section 4.6).

4.4 Special warnings and precautions for use

- Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take metronidazole as this product contains lactose.
- Patients should abstain from alcohol for at least 48 hours following discontinuation of therapy with metronidazole. A disulfiram-like reaction with hypotension and flushing has occurred (see section 4.5).
- Caution is advised in patients with porphyria.
- Metronidazole tablets should not be used in patients with blood dyscrasias or with active non-infectious disease of the central nervous system. High doses of metronidazole may mask the presence of syphilis.
- Caution in patients with epilepsy or those who have had seizures as high doses of Metronidazole can induce seizures.
- Use with caution in the second and third trimester when used to treat trichomoniasis or bacterial vaginosis (see section 4.6.)
- Regular clinical and laboratory surveillance are advised if treatment continues for more than 10 days.
- Consideration of the therapeutic benefit against the risk of peripheral neuropathy is advised with continuous therapy for chronic conditions.
- There is a possibility that after *Trichomonas vaginalis* has been eliminated a gonococcal infection might persist.
- The elimination half-life of metronidazole remains unchanged in the presence of renal failure. The dosage of metronidazole, therefore, needs no reduction. Such patients, however, retain the metabolites of metronidazole. The clinical significance of this is not known at present.
- In patients undergoing haemodialysis metronidazole and metabolites are efficiently removed during an eight-hour period of dialysis. Metronidazole should, therefore, be readministered immediately after haemodialysis.
- No routine adjustment in the dosage of metronidazole need be made in patients with renal failure undergoing intermittent peritoneal dialysis (IPD) or continuous ambulatory peritoneal dialysis (CAPD).
- Metronidazole is mainly metabolised by hepatic oxidation. Substantial impairment of metronidazole clearance may occur in the presence of advanced hepatic insufficiency. Significant cumulation may occur in patients with hepatic encephalopathy and the resulting high plasma concentrations of metronidazole may contribute to symptoms of the encephalopathy. Therefore, metronidazole should be administered with caution to patients with hepatic encephalopathy. The daily dosage should be reduced to one third and may be administered once daily.

4.5 Interaction with other medicinal products and other forms of interaction

- Interactions to be used with caution:
 - *Lithium*: Lithium retention accompanied by evidence of possible renal damage has been reported in patients treated simultaneously with lithium and metronidazole. Lithium treatment should be tapered or withdrawn before administering metronidazole. Plasma concentration of lithium, creatinine, and electrolytes should be monitored in patients under treatment with lithium while they receive metronidazole.

- *Anticoagulants:* Some potentiation of anticoagulant therapy has been reported when metronidazole has been used with the warfarin type oral anticoagulants. Dosage of the latter may require reducing. Prothrombin times should be monitored. No interactions have been reported with anticoagulants of the heparin type. However, anticoagulant activity should be routinely monitored with these products.
- *Alcohol:* Patients should be advised not to take alcohol during metronidazole therapy and for at least 48 hours after because of the possibility of a disulfiram-like reaction.
- *Disulfiram:* Psychotic reactions have been reported.
- *Immunosuppressants:* Patients receiving ciclosporin are at risk of elevated ciclosporin serum levels. Serum ciclosporin and serum creatinine should be closely monitored when coadministration is necessary.
- Pharmacokinetic interactions:
 - *Antiepileptics:* Patients receiving phenobarbital metabolise metronidazole at a much greater rate than normally, reducing the half-life to approximately 3 hours. Metronidazole inhibits metabolism of phenytoin (increases plasma-phenytoin concentration). Primidone accelerates the metabolism of Metronidazole causing reduced plasma concentrations.
 - *Cytotoxics:* Metronidazole inhibits metabolism of fluorouracil. Therefore, increased toxicity of fluorouracil can result.
 - *Ulcer-healing drugs:* Cimetidine inhibits the metabolism of metronidazole (increases plasma-metronidazole concentration).
 - *Oestrogens:* broad spectrum antibiotics possibly reduce the contraceptive effect. See local/national guidelines or BNF for specific advice.
 - *Drug-lab modifications:* Aspartate amino transferase assays may give spuriously low values in patients taking metronidazole, depending on the method used.

4.6 Pregnancy and lactation

As with all medicines, metronidazole should not be given during pregnancy or during lactation unless it is considered essential, and in these circumstances the short, high-dosage regimens are not recommended.

Metronidazole is contraindicated in the first trimester (see section 4.3) and should be used with caution in the second and third trimester when used to treat trichomoniasis or bacterial vaginosis (see section 4.4).

For all other indications Metronidazole should only be used if the benefits outweigh the risks or no other alternative is available especially in the first trimester.

It is advisable to stop breast feeding until 12 – 24 hours after Metronidazole therapy has been discontinued when single high doses have been used (see section 4.3).

4.7 Effects on ability to drive and use machines

Patients should be warned about the potential for drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders, and advised not to drive or operate machinery if these symptoms occur.

4.8 Undesirable effects

Serious adverse reactions occur very rarely with standard recommended regimens.

- *Hypersensitivity reactions:* Urticaria, fever and angioedema occur occasionally. Anaphylaxis may occur rarely.
- *Blood and lymphatic system disorders:* There have been reports of bone marrow depression disorders such as aplastic anaemia, agranulocytosis, neutropenia, leucopenia, thrombocytopenia and pancytopenia which may be reversed on drug withdrawal, although fatalities have been reported.
- *Nervous system disorders:* Drowsiness, dizziness, headache, ataxia, depression, paraesthesia, incoordination of movement has been reported very rarely. Transient visual disorders, such as diplopia and myopia, have been reported very rarely. Psychotic disorders, including confusion and hallucinations, have been reported very rarely. During intensive and/or prolonged metronidazole therapy, a few instances of peripheral neuropathy or transient epileptiform seizures have been reported. In most cases neuropathy disappeared after treatment was stopped or when dosage was reduced.
- *Gastrointestinal disorders:* Unpleasant taste in the mouth, furred tongue, taste disorders, oral mucositis, nausea, vomiting, diarrhoea, abdominal pain, anorexia and gastro-intestinal disturbances occur occasionally.
- *Hepatobiliary disorders:* Metronidazole may result in hepatotoxicity and reactions such as abnormal liver function tests, cholestatic hepatitis, pancreatitis and jaundice have been reported very rarely which may be reversed upon drug withdrawal.
- *Skin and subcutaneous tissue disorders:* pruritus, skin rashes and pustular eruptions have been reported very rarely and metronidazole treatment has been documented to be associated with erythema multiforme which may be reversed on drug withdrawal.
- *Musculoskeletal, connective tissue and bone disorders:* myalgia and arthralgia has been reported very rarely.
- *Renal and urinary disorders:* darkening of the urine (due to metronidazole metabolite) have been reported but very rarely.

4.9 Overdose

Features:

Nausea, vomiting, diarrhoea, anorexia, metallic taste, headache, dizziness and occasionally insomnia and drowsiness. Transiently increased liver enzyme activities have been reported rarely.

Transient epileptiform seizures have been reported following intensive or prolonged therapy. Other adverse effects occurring in these circumstances include peripheral motor neuropathy, blood dyscrasias and liver damage.

The combination of alcohol and metronidazole has been said to cause disulfiram type reactions in about 10% of individuals with sudden onset of excitement, giddiness, flushing, nausea, headache, hypotension and dyspnoea. However the mechanism of this reaction has been questioned.

Treatment:

Unlikely to be required.

Disulfiram type reactions should be treated with intravenous fluids and plasma expanders if necessary. Symptomatic and supportive.

In more serious cases:

1. Single brief convulsions do not require treatment. If frequent or prolonged control with intravenous diazepam (10-20mg in adults; 0.1-0.3mg/kg body weight) or lorazepam (4mg in an adult and 0.05mg/kg in a child). Give oxygen and correct acid base and metabolic disturbances as required.
2. Other measures as indicated by the patient's clinical condition.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

ATC Code: P01A B01

Metronidazole has antiprotozoan and antibacterial effects. Its effects against *Trichomonas vaginalis*, *Gardnerella vaginalis* and other protozoa including *Entamoeba histolytica*, *Gardia lamblia* and anaerobic bacteria.

5.2 Pharmacokinetic properties

Absorption - Metronidazole is readily absorbed following administration by mouth and bioavailability is 90-100%. Peak plasma concentrations of approximately 5µg/ml and 10µg/ml are achieved an average of 1-2 hours after single doses of 250mg and 500mg respectively. Some accumulation and consequently higher concentrations occur when multiple doses are given. Absorption may be delayed, but is not reduced overall, by administration with food.

Distribution - Metronidazole is widely distributed. It appears in most body tissues and fluids. It also crosses the placenta and rapidly enters foetal circulation. No more than 20% is bound to plasma proteins.

Metabolism - Metronidazole is metabolised in the liver by side-chain oxidation and glucuronide formation. The plasma elimination half-life of metronidazole is about 6-9 hours; that of the hydroxy metabolite is slightly longer. The half-life of metronidazole is reported to be longer in neonates and in patients with severe liver disease.

Elimination - The majority of a dose of metronidazole is excreted in the urine, mainly as metabolites; a small amount appears in the faeces.

5.3 Preclinical safety data

Not applicable.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Also contains: carmellose sodium, cellulose, colloidal silica, lactose, magnesium stearate, maize starch, polyethylene glycol, titanium dioxide (E171), hydroxypropylcellulose (E463), methylhydroxypropylcellulose (E464), water.

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf-life

Three years from the date of manufacture.

Shelf-life after dilution/reconstitution

Not applicable.

Shelf-life after first opening

Not applicable.

6.4 Special precautions for storage

Store below 25°C in a dry place.

6.5 Nature and contents of container

The product containers are rigid injection moulded polypropylene or injection blow-moulded polyethylene containers and snap-on polyethylene lids; in case any supply difficulties should arise the alternative is amber glass bottles with screw caps. An alternative closure for polyethylene containers is a polypropylene, twist on, push down and twist off child-resistant, tamper-evident lid.

The product may also be supplied in blister packs in cartons:

a) Carton: Printed carton manufactured from white folding box board.

b) Blister pack: (i) 250µm white rigid PVC. (ii) Surface printed 20µm hard temper aluminium foil with 5-7g/M² PVC and PVdC compatible heat seal lacquer on the reverse side.

Pack size: 14s, 20s, 21s, 28s, 30s, 50s, 56s, 60s, 84s, 90s, 100s, 112s, 120s, 168s, 180s, 250s, 500s, 1000s.

Product may also be supplied in bulk packs, for reassembly purposes only, in polybags contained in tins, skillets or polybuckets filled with suitable cushioning material. Bulk packs are included for *temporary* storage of the finished product before final packaging into the proposed marketing containers.

Maximum size of bulk packs: 25,000.

6.6 Special precautions for disposal

Not applicable.

7 MARKETING AUTHORISATION HOLDER

Name or style and permanent address of registered place of business of the holder of the Marketing Authorisation:

Actavis UK Limited
(Trading style: Actaivs)
Whiddon Valley
BARNSTAPLE
N Devon EX32 8NS

8 MARKETING AUTHORISATION NUMBER(S)

PL 0142/0250

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

12.06.87 / 21.10.02

10 DATE OF REVISION OF THE TEXT

June 2007

11 DOSIMETRY (IF APPLICABLE)

12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS (IF APPLICABLE)